Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05747404
Other study ID # 09C040
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date April 21, 2020
Est. completion date April 21, 2027

Study information

Verified date April 2024
Source Istituto Auxologico Italiano
Contact Luigi Badano, MD, Ph.D.
Phone +3902619112319
Email l.badano@auxologico.it
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Prospective, multicenter, observational study to enroll consecutive patients with functional tricuspid regurgitation (FTR) with the primary aim to: - Use patients' outcomes as a reference to try to define the threshold values for the different grades of FTR severity; and secondary aims to: - Use 3D echocardiography to assess the relationships among the geometry (size and shape) of the right ventricle, right atrium, tricuspid annulus, and tricuspid leaflets according to the underlying cardiac condition (i.e., atrial fibrillation, pulmonary hypertension, right ventricular cardiomyopathy, congenital heart diseases, etc.) - Assess the accuracy, and incremental diagnostic and prognostic value of a new software package to measure tricuspid annulus and valve geometry - Develop new parameters of FTR severity that take into account the lower momentum of the tricuspid regurgitant jet (compared with the mitral regurgitation jet), the complex anatomy of the regurgitant orifice, and both the intra-beat and respiratory variation of the regurgitant volume - Test the hypothesis that there is no actual grading but a continuum of increased risk of adverse outcome with the increase of FTR severity, and we need robust quantitative metrics (for example, the regurgitant fraction - currently not included in guidelines - which takes into account the right ventricular volume and function) more than grading schemes to assess the severity of the diseases and the effect of treatments - Test the hypothesis that the relationship between FTR severity and the outcome may be different according to the underlying cardiac condition (i.e., atrial fibrillation, pulmonary hypertension, right ventricular cardiomyopathy, congenital heart diseases, post-cardiac surgery, etc.) as this will affect the timing for interventions


Recruitment information / eligibility

Status Recruiting
Enrollment 1500
Est. completion date April 21, 2027
Est. primary completion date April 1, 2025
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - older than 18 years, - signed informed consent to be part of this study, - no pregnancy, - the presence of at least one of the following cardiac conditions: a. Permanent atrial fibrillation b. Pulmonary arterial hypertension c. Left heart diseases with increased postcapillary pressure d. Right ventricular cardiomyopathy e. Right ventricular infarction f. Chronic thromboembolic pulmonary embolism g. Congenital diseases with right ventricular volume overload (atrial septal defect, interventricular septal defect, pulmonary regurgitation) h. Previous left heart valve surgery I. Good enough acoustic window and patient cooperation to obtain 3D echo data sets of the right ventricle, right atrium and tricuspid valve with a minimum temporal resolution of 20 vps l. Availability for clinical and echocardiography follow-up Exclusion Criteria: - Unwillingness to be part of the study - Primary tricuspid valve disease - Patient already scheduled for tricuspid valve repair/replacement - Cardiac pacemaker, ICD or CRT leads - Poor acoustic window - Impossibility of left lateral decubitus position - Extreme heart rates (<50 or >100 bpm) - Previous LVAD implantation

Study Design


Intervention

Diagnostic Test:
Echocardiography
- Develop new parameters of FTR severity that take into account the lower momentum of the tricuspid regurgitant jet (compared with the mitral regurgitation jet), the complex anatomy of the regurgitant orifice, and both the intra-beat and respiratory variation of the regurgitant volume

Locations

Country Name City State
Italy Istituto Auxologico Italiano, IRCCS Milan
Italy University of Padova Padova
Romania University of Medicine and Pharmacy Carol Davila Bucharest
Romania University of Medicine and Pharmacy of Craiova Craiova

Sponsors (1)

Lead Sponsor Collaborator
Istituto Auxologico Italiano

Countries where clinical trial is conducted

Italy,  Romania, 

Outcome

Type Measure Description Time frame Safety issue
Other Right heart remodeling in various cardiac conditions affecting the right heart Use 3D echocardiography to assess the relationships among the geometry (size and shape) of the right ventricle, right atrium, tricuspid annulus and tricuspid leaflets according to the underlying cardiac condition (i.e. atrial fibrillation, pulmonary hypertension, right ventricular cardiomyopathy, congenital heart diseases etc.) 5 years
Other 3D echo software validation Assess the accuracy, and incremental diagnostic and prognostic value of a new software package to measure tricuspid annulus and valve geometry 1 year
Other Improve grading of FTR Develop new parameters of FTR severity that take into account the lower momentum of the tricuspid regurgitant jet (compared with the mitral regurgitation jet), the complex anatomy of the regurgitant orifice, and bot the intra-beat and respiratory variation of the regurgitant volume 2 years
Other Clinical significance of categorical grading Test the hypothesis that there is no actual grading, but a continuum of increased risk of adverse outcome with the increase of FTR severity and we need robust quantitative metrics (for example the regurgitant fraction - currently not included in guidelines - which takes into account the right ventricular volume and function) more than grading schemes to assess the severity of the diseases and the effect of treatments 5 years
Other Define different phenotypes of FTR Test the hypothesis that the relationship between FTR severity and outcome may be different according to the underlying cardiac condition (i.e. atrial fibrillation, pulmonary hypertension, right ventricular cardiomyopathy, congenital heart diseases, post-cardiac surgery etc.) as this will affect the timing for interventions 5 years
Primary Composite endpoint death from any cause and hospitalization for heart failure 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT05114551 - ICU Predictive Score of WEaning Success in Patients At Risk of Extubation Failure
Completed NCT03088943 - Intraoperative Diastolic Function by TDI and STE N/A